No detriment to quality of life (QOL) was seen 1 year after treatment with cediranib in patients with platinum-sensitive relapsed ovarian cancer, a study published in the journal Cancer has shown.1

Researchers at St. James’s Institute of Oncology at the University of Leeds, Leeds, United Kingdom, found that the maintenance of QOL, along with prolonged cancer control, suggests that cediranib has a valuable role in the treatment of relapsed ovarian cancer.

The ICON6 trial demonstrated that cediranib improved clinical outcomes for patients with platinum-sensitive relapsed ovarian cancer concurrent with chemotherapy and continued as maintenance therapy, the researchers report. The current study examined QOL after 52 weeks.

For the study, 456 women were randomly assigned to standard chemotherapy only, chemotherapy with concurrent cediranib, or chemotherapy with cediranib administered concurrently and continued as maintenance. QOL questionnaires were completed every 3 weeks during chemotherapy then every 6 weeks to 52 weeks, until disease progression.

The researchers found that the mean global QOL score at 52 weeks was 62.6 points for the standard chemotherapy group compared with 68.7 points for the concurrent-maintenance group. When the investigators examined the self-reported symptom data they found that diarrhea the main toxicity with cediranib treatment. Better control of diarrhea suggests QOL scores could be significantly improved. 

Reference

1. Stark DP, Cook A, Brown JM, et al. Quality of life with cediranib in relapsed ovarian cancer: the ICON6 phase 3 randomized clinical trial. Cancer. 2017 Mar 24. doi: 10.1002/cncr.30657 [Epub ahead of print]